Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 14/20 | 0.61 |
| ▸ | CTSS | P25774 | 7/20 | 0.60 |
| ▸ | CTSL | P07711 | 7/20 | 0.60 |
| ▸ | CTSB | P07858 | 2/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4660369 | 1.00 | CTSK (0.61) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL2147583 | 1.00 | CTSK (0.61) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL10610800 | 0.91 | CTSK (0.63) | CTSKCTSSCTSLCTSB | |
| SCHEMBL10610794 | 0.91 | CTSK (0.63) | CTSKCTSSCTSLCTSB | |
| SCHEMBL11209608 | 0.90 | CTSK (0.71) | CTSKCTSSCTSLCTSB | |
| SCHEMBL6014223 | 0.90 | CTSK (0.71) | CTSKCTSSCTSLCTSB | |
| SCHEMBL7175459 | 0.89 | CTSK (0.57) | CTSKCTSSCTSLCTSB | |
| SCHEMBL7412569 | 0.88 | CTSK (0.68) | CTSKCTSSCTSLCTSB | |
| SCHEMBL14923512 | 0.88 | CTSK (0.68) | CTSKCTSSCTSLCTSB | |
| SCHEMBL16847832 | 0.88 | CTSK (0.60) | CTSKCTSSCTSLCTSBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1115390-B1 | HYDROXAMATE-CONTAINING CYSTEINE AND SERINE PROTEASE INHIBITORS | CEPHALON INC (US) | 2009-07-22 | — | — | EP | claimed |
| US-7060683-B2 | Hydroxamate-containing cysteine and serine protease inhibitors | CEPHALON, INC. (US) | 2006-06-13 | — | — | US | claimed |
| EP-1115390-A4 | HYDROXAMATE-CONTAINING CYSTEINE AND SERINE PROTEASE INHIBITORS | CEPHALON INC (US) | 2004-08-11 | — | — | EP | claimed |
| US-20040106558-A1 | Hydroxamate-containing cysteine and serine protease inhibitors | CEPHALON, INC. | 2004-06-03 | — | — | US | claimed |
| US-6686335-B1 | INHIBITING CALPAIN | CEPHALON, INC. | 2004-02-03 | — | — | US | claimed |
| EP-1115390-A1 | HYDROXAMATE-CONTAINING CYSTEINE AND SERINE PROTEASE INHIBITORS | CEPHALON, INC. (US) | 2001-07-18 | — | — | EP | claimed |
| WO-2000016767-A1 | HYDROXAMATE-CONTAINING CYSTEINE AND SERINE PROTEASE INHIBITORS | CEPHALON, INC. (US) | 2000-03-30 | — | — | WO | claimed |
| US-4350628-A | OXIDATIVE DEHYDROGENATION WITH A BENZOQUINONE | RESEARCH CORPORATION (US) | 1982-09-21 | — | — | US | claimed |
| EP-1115390-B1 | HYDROXAMATE-CONTAINING CYSTEINE AND SERINE PROTEASE INHIBITORS | CEPHALON INC (US) | 2009-07-22 | — | — | EP | disclosed |
| US-7060683-B2 | Hydroxamate-containing cysteine and serine protease inhibitors | CEPHALON, INC. (US) | 2006-06-13 | — | — | US | disclosed |
| EP-1115390-A4 | HYDROXAMATE-CONTAINING CYSTEINE AND SERINE PROTEASE INHIBITORS | CEPHALON INC (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040106558-A1 | Hydroxamate-containing cysteine and serine protease inhibitors | CEPHALON, INC. | 2004-06-03 | — | — | US | disclosed |
| US-6686335-B1 | INHIBITING CALPAIN | CEPHALON, INC. | 2004-02-03 | — | — | US | disclosed |
| EP-1115390-A1 | HYDROXAMATE-CONTAINING CYSTEINE AND SERINE PROTEASE INHIBITORS | CEPHALON, INC. (US) | 2001-07-18 | — | — | EP | disclosed |
| US-6008228-A | COMPRISING A MIXTURE OF CARRIER MONOGLYCERIDES OF MEDIUM CHAIN-FATTY ACIDS | HOFFMAN-LA ROCHE INC. (US) | 1999-12-28 | — | — | US | disclosed |
| EP-0594540-B1 | Antiretroviral acyl compounds | CIBA GEIGY AG (CH) | 1998-04-01 | — | — | EP | disclosed |
| EP-0831826-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PROTEINASE INHIBITOR AND A MONOGLYCERIDE | F. HOFFMANN-LA ROCHE AG (CH) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996039142-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PROTEINASE INHIBITOR AND A MONOGLYCERIDE | F. HOFFMANN-LA ROCHE AG (CH) | 1996-12-12 | — | — | WO | disclosed |
| EP-0594540-A1 | Antiretroviral acyl compounds | CIBA-GEIGY AG (CH) | 1994-04-27 | — | — | EP | disclosed |
| EP-0386611-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1990-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106558-A1 | Hydroxamate-containing cysteine and serine protease inhibitors | HPN, SPINT2, PRSS1 | CTSK 77/4885CTSS 57/4885CTSL 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.